Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy.
J Clin Pathol. 2012 Feb;65(2):183-5. doi: 10.1136/jclinpath-2011-200342. Epub 2011 Oct 29.
A significant proportion of breast cancers with HER2 amplification show simultaneous amplification or deletion of Topo 2. Amplification of Topo 2 may lead to the overexpression of the Topo 2 protein and ultimately to hypersensitivity to Topo 2 inhibitors. HER2 and Topo 2 gene status in breast cancer patients has been determined in several studies using immunohistochemistry, florescence in situ hybridisation (FISH) and multiplex ligation-dependent probe amplification (MLPA). Although comparisons of FISH and MLPA have been reported for HER2, it is believed that there are no similar studies for Topo 2. In this study, HER2 and Topo 2 were analysed by MLPA and FISH. There was a high agreement between the two approaches, although MLPA was easier to perform and cheaper than FISH. In conclusion, MLPA is a fast and accurate quantitative method to detect HER2 and Topo 2 amplification, and could be considered a good alternative to FISH.
相当一部分 HER2 扩增的乳腺癌同时显示 Topo 2 的扩增或缺失。Topo 2 的扩增可能导致 Topo 2 蛋白的过表达，并最终导致对 Topo 2 抑制剂的过度敏感。已经使用免疫组织化学、荧光原位杂交 (FISH) 和多重连接依赖性探针扩增 (MLPA) 在几项研究中确定了乳腺癌患者的 HER2 和 Topo 2 基因状态。尽管已经有报道比较了 FISH 和 MLPA 用于 HER2，但据信没有针对 Topo 2 的类似研究。在这项研究中，通过 MLPA 和 FISH 分析了 HER2 和 Topo 2。这两种方法之间具有高度一致性，尽管 MLPA 比 FISH 更容易进行且成本更低。总之，MLPA 是一种快速而准确的定量方法，可用于检测 HER2 和 Topo 2 的扩增，并且可以被认为是 FISH 的良好替代方法。
